Horizon Presents Results of Uplizna (inebilizumab-cdon) in N-MOmentum Trial for NMOSD at AAN 2021
Shots:
- The company reported the data from the N-MOmentum trial involves assessing Uplizna in patients with NMOSD
- The results from the N-MOmentum trial demonstrated a reduction in pain- long-term safety- and efficacy outcomes. Additional results from the new survey demonstrated NMOSD patient attitudes towards diagnosis and treatment
- Uplizna is the first FDA-approved B-cell depleter to treat adult patients with AQP4 antibody-positive NMOSD
Ref: Horizon | Image: Horizon
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com